Mineralys Therapeutics (NASDAQ:MLYS) versus IntelGenx Technologies (OTCMKTS:IGXT) Head-To-Head Comparison

Mineralys Therapeutics (NASDAQ:MLYS) and IntelGenx Technologies (OTCMKTS:IGXT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, dividends and institutional ownership.

Insider and Institutional Ownership

84.5% of Mineralys Therapeutics shares are held by institutional investors. 62.7% of IntelGenx Technologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Mineralys Therapeutics and IntelGenx Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mineralys Therapeutics	N/A	-26.48%	-25.52%
IntelGenx Technologies	-955.44%	N/A	-128.18%

Analyst Recommendations

This is a summary of current recommendations and price targets for Mineralys Therapeutics and IntelGenx Technologies, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mineralys Therapeutics	0	0	3	0	3.00
IntelGenx Technologies	0	0	0	0	N/A

Mineralys Therapeutics currently has a consensus target price of $33.50, suggesting a potential upside of 152.64%. Given Mineralys Therapeutics’ higher possible upside, equities analysts plainly believe Mineralys Therapeutics is more favorable than IntelGenx Technologies.

Earnings & Valuation

This table compares Mineralys Therapeutics and IntelGenx Technologies’ revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mineralys Therapeutics	N/A	N/A	-$71.90 million	($2.00)	-6.63
IntelGenx Technologies	$1.04 million	28.38	-$9.93 million	($0.06)	-2.82

IntelGenx Technologies has higher revenue and earnings than Mineralys Therapeutics. Mineralys Therapeutics is trading at a lower price-to-earnings ratio than IntelGenx Technologies, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Mineralys Therapeutics has a beta of 2.36, indicating that its stock price is 136% more volatile than the S&P 500. Comparatively, IntelGenx Technologies has a beta of 2.43, indicating that its stock price is 143% more volatile than the S&P 500.

Summary

IntelGenx Technologies beats Mineralys Therapeutics on 7 of the 12 factors compared between the two stocks.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

About IntelGenx Technologies

IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 and INT0055/2021 are for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also developing INT0039/2013, INT0053/2020, and INT0054/2020. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was incorporated in 1999 and is headquartered in Montreal, Canada.